CorMedix (CRMD) Stock Price, News & Analysis

Company Overview

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing products designed to prevent and treat infectious and inflammatory complications associated with medical devices and procedures. The company’s lead product is DefenCath (taurolidine and heparin), an antimicrobial catheter lock solution intended to help reduce catheter-related bloodstream infections in adult patients receiving chronic hemodialysis through central venous catheters.

DefenCath was approved by the U.S. Food and Drug Administration in 2023 and is marketed in the United States for use in the hemodialysis setting. The product is instilled into a catheter between dialysis sessions and is designed to help protect against microbial colonization and infection. CorMedix has focused its commercialization efforts on dialysis providers, hospitals, and other healthcare organizations that manage patients with long-term central venous access.

CorMedix was established to develop anti-infective solutions for patients who rely on implanted or indwelling medical devices. In addition to its commercial activities surrounding DefenCath, the company has evaluated taurolidine-based formulations and related applications in other clinical settings. CorMedix is headquartered in Berkeley Heights, New Jersey, and its business is primarily focused on the U.S. healthcare market.

Key Stats

• Today's Range: $7.63 to $8.19
• 50-Day Range: $7.10 to $8.61
• 52-Week Range: $6.13 to $13.02
• Volume: 495,042 shs
• Average Volume: 1.63 million shs
• Market Capitalization: $595.07 million
• P/E Ratio: 3.57
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Moderate Buy

CorMedix Stock Analysis - MarketRank™

CorMedix scored higher than 50% of companies evaluated by MarketBeat, and ranked 553rd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

CorMedix has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 7 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

CorMedix has a consensus price target of $15.00, representing about 96.2% upside from its current price of $7.65.

Amount of Analyst Coverage

CorMedix has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -74.07%

Earnings Growth

Earnings for CorMedix are expected to decrease by -74.07% in the coming year, from $0.54 to $0.14 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CorMedix is 3.59, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.05.

Price to Earnings Ratio vs. Sector

The P/E ratio of CorMedix is 3.59, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.68.

Price to Book Value per Share Ratio

CorMedix has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

21.31% of the float of CorMedix has been sold short.

Short Interest Ratio / Days to Cover

CorMedix has a short interest ratio ("days to cover") of 12.98, which indicates bearish sentiment.

Change versus previous month

Short interest in CorMedix has recently decreased by 6.52%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CorMedix does not currently pay a dividend.

Dividend Growth

CorMedix does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for CorMedix this week, compared to 5 articles on an average week.

Search Interest

10 people have searched for CRMD on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added CorMedix to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CorMedix insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.50% of the stock of CorMedix is held by insiders.

Percentage Held by Institutions

34.18% of the stock of CorMedix is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/23/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CRMD
• CIK: 1410098
• Web: www.cormedix.com
• Phone: (908) 517-9500
• Fax: 908-429-4307
• Employees: 191
• Year Founded: 2006

Price Target and Rating

• Average Price Target for CorMedix: $15.00
• High Price Target: $19.00
• Low Price Target: $13.00
• Potential Upside/Downside: +96.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.14
• Trailing P/E Ratio: 3.57
• Forward P/E Ratio: 14.16
• P/E Growth: N/A
• Net Income: $163.05 million
• Net Margins: 40.49%
• Pretax Margin: 44.00%
• Return on Equity: 40.52%
• Return on Assets: 20.61%

Debt

• Debt-to-Equity Ratio: 0.31
• Current Ratio: 2.56
• Quick Ratio: 2.36

Sales & Book Value

• Annual Sales: $311.71 million
• Price / Sales: 1.91
• Cash Flow: $2.01 per share
• Price / Cash Flow: 3.80
• Book Value: $5.14 per share
• Price / Book: 1.49

Miscellaneous

• Outstanding Shares: 77,940,000
• Free Float: 75,216,000
• Market Cap: $595.85 million
• Optionable: Optionable
• Beta: 1.50